This company listing is no longer active
Paion Past Earnings Performance
Past criteria checks 0/6
Paion's earnings have been declining at an average annual rate of -2.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 34.5% per year.
Key information
-2.3%
Earnings growth rate
1.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 34.5% |
| Return on equity | n/a |
| Net Margin | -134.1% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Here's Why We're Not At All Concerned With Paion's (ETR:PA8) Cash Burn Situation
Nov 17
Results: Paion AG Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 03Paion AG's (ETR:PA8) Stock Has Fared Decently: Is the Market Following Strong Financials?
Feb 09
Did You Miss Paion's (ETR:PA8) 28% Share Price Gain?
Dec 15Revenue & Expenses Breakdown
How Paion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 15 | -20 | 20 | 5 |
| 31 Mar 23 | 24 | -10 | 21 | 6 |
| 31 Dec 22 | 33 | -1 | 21 | 6 |
| 30 Sep 22 | 27 | -3 | 22 | 6 |
| 30 Jun 22 | 29 | -2 | 21 | 5 |
| 31 Mar 22 | 18 | -12 | 21 | 5 |
| 31 Dec 21 | 7 | -22 | 20 | 5 |
| 30 Sep 21 | 6 | -20 | 15 | 6 |
| 30 Jun 21 | 20 | -2 | 13 | 7 |
| 31 Mar 21 | 18 | -1 | 10 | 8 |
| 31 Dec 20 | 20 | 2 | 8 | 10 |
| 30 Sep 20 | 20 | 2 | 7 | 12 |
| 30 Jun 20 | 4 | -14 | 6 | 13 |
| 31 Mar 20 | 12 | -5 | 6 | 14 |
| 31 Dec 19 | 8 | -7 | 5 | 13 |
| 30 Sep 19 | 10 | -5 | 4 | 13 |
| 30 Jun 19 | 10 | -3 | 4 | 12 |
| 31 Mar 19 | 3 | -10 | 4 | 12 |
| 31 Dec 18 | 3 | -10 | 3 | 12 |
| 30 Sep 18 | 1 | -12 | 4 | 13 |
| 30 Jun 18 | 2 | -13 | 4 | 14 |
| 31 Mar 18 | 4 | -13 | 4 | 17 |
| 31 Dec 17 | 6 | -12 | 4 | 18 |
| 30 Sep 17 | 7 | -13 | 4 | 21 |
| 30 Jun 17 | 8 | -13 | 4 | 21 |
| 31 Mar 17 | 6 | -16 | 5 | 21 |
| 31 Dec 16 | 4 | -20 | 5 | 23 |
| 30 Sep 16 | 2 | -24 | 5 | 25 |
| 30 Jun 16 | 0 | -30 | 6 | 30 |
| 31 Mar 16 | 0 | -30 | 6 | 30 |
| 31 Dec 15 | 0 | -28 | 6 | 29 |
| 30 Sep 15 | 2 | -23 | 6 | 26 |
| 30 Jun 15 | 2 | -17 | 5 | 19 |
| 31 Mar 15 | 3 | -12 | 4 | 16 |
| 31 Dec 14 | 3 | -9 | 4 | 12 |
| 30 Sep 14 | 5 | -5 | 4 | 8 |
| 30 Jun 14 | 5 | -4 | 3 | 7 |
| 31 Mar 14 | 3 | -4 | 3 | 5 |
| 31 Dec 13 | 4 | -2 | 3 | 5 |
| 30 Sep 13 | 4 | -3 | 4 | 4 |
| 30 Jun 13 | 5 | -2 | 4 | 3 |
| 31 Mar 13 | 17 | 7 | 4 | 3 |
Quality Earnings: PA8 is currently unprofitable.
Growing Profit Margin: PA8 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PA8 is unprofitable, and losses have increased over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare PA8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PA8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: PA8's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.